Press releases

4
Jun 2018
20:30 E.S.T.

FDA Grants Cellectis IND Approval for UCART22 in B-ALL

Read more
22
May 2018
23:15 E.S.T.

Approval of UCART123 Amendment in AML to Accelerate Clinical Development

Read more
22
May 2018
20:00 E.S.T.

Calyxt Announces Successful Closing of $60.9 Million Public Offering

Read more
21
May 2018
12:30 E.S.T.

Calyxt Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

Read more
18
May 2018
12:55 E.S.T.

Calyxt Announces Upsizing and Pricing of Follow-On Offering

Read more
15
May 2018
21:45 E.S.T.

Calyxt Announces Launch of Proposed Follow-On Offering

Read more
10
May 2018
21:15 E.S.T.

Cellectis to Present Data at the 2018 ASGCT Annual Meeting

Read more
7
May 2018
20:30 E.S.T.

Cellectis Reports 1st Quarter 2018 Financial Results

Read more
2
May 2018
20:30 E.S.T.

Cellectis Files IND for UCART22 in Acute Lymphoblastic Leukemia (B-ALL)

Read more
1
May 2018
11:00 E.S.T.

Harvard’s Wyss Institute partners with Cellectis to recode the human genome

Read more

Press contacts

For more information on any story, or for press enquiries, get in touch with our communication team

CONTACT US